Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

Velcade Plus Dex Improves Survival Of Multiple Myeloma Patients With 4/14 Chromosome Deletion When Used During Induction

Home/Velcade Plus Dex Improves Survival Of Multiple Myeloma Patients With 4/14 Chromosome Deletion When Used During Induction

Velcade Plus Dex Improves Survival Of Multiple Myeloma Patients With 4/14 Chromosome Deletion When Used During Induction

OncologyStat.com reports there is some good news for multiple myeloma patients with chromosomal abnormalities:
Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
TAKE-HOME MESSAGE

In this large, retrospective analysis of patients with newly diagnosed multiple myeloma, bortezomib-based induction therapy before high-dose melphalan and stem cell transplantation was associated with improved survival in patients with t(4;14) but not del(17p) cytogenetics when compared with patients who received vincristine, doxorubicin, and dexamethasone induction.

Please note patients with 17p deletions did not see much benefit.  This report is a must read for any patient with chromosomal issues.  Go to:  Vel/Dex Shows Survival Benefit For Some for more.
 
Feel good and keep smiling!  Pat